-
Mashup Score: 14SABCS24 ONCOALERT | ONCOBITES - 5 month(s) ago
In an interview, Dr. Agostinetto delves into the findings of Dr. Souza, who shares the results of his research explaining why larotrectinib is positioned as an effective and safe treatment option for patients with TRK fusion breast cancer. Dr. Cristiano de P á dua Souza MD, Jules Bordet Institute, Brussels,
Source: www.oncobites.tvCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 10SABCS24 ONCOALERT | ONCOBITES - 6 month(s) ago
In an interview, Dr. Agostinetto delves into the findings of Dr. Souza, who shares the results of his research explaining why larotrectinib is positioned as an effective and safe treatment option for patients with TRK fusion breast cancer. Dr. Cristiano de P á dua Souza MD, Jules Bordet Institute, Brussels,
Source: www.oncobites.tvCategories: General Medicine News, Oncologists1Tweet-
Join our collaborators at @OncobitesTv for an interview featuring @DrCrisPadua as he shares research on larotrectinib as an effective tx for TRK fusion #BreastCancer #SABCS24 Link to view: https://t.co/IHi0sALPjO Dr. @ElisaAgostinett Elisa Agostinetto from the Jules… https://t.co/6JvXP1Kh33 https://t.co/wmD1obxNaJ
-
-
Mashup Score: 20SABCS24 ONCOALERT | ONCOBITES - 6 month(s) ago
In an interview, Dr. Agostinetto delves into the findings of Dr. Souza, who shares the results of his research explaining why larotrectinib is positioned as an effective and safe treatment option for patients with TRK fusion breast cancer. Dr. Cristiano de P á dua Souza MD, Jules Bordet Institute, Brussels,
Source: www.oncobites.tvCategories: General Medicine News, Oncologists1Tweet-
Join our collaborators at @OncobitesTv for an interview featuring @DrCrisPadua as he shares research on larotrectinib as an effective treatment for TRK fusion breast cancer. Link: https://t.co/k9RIIRx7nl Dr. @ElisaAgostinett Elisa Agostinetto from the Jules Bordet Institute in… https://t.co/YPDzOVivRA https://t.co/I59Ldib4g1
-
-
Mashup Score: 20SABCS24 ONCOALERT | ONCOBITES - 6 month(s) ago
In an interview, Dr. Agostinetto delves into the findings of Dr. Souza, who shares the results of his research explaining why larotrectinib is positioned as an effective and safe treatment option for patients with TRK fusion breast cancer. Dr. Cristiano de P á dua Souza MD, Jules Bordet Institute, Brussels,
Source: www.oncobites.tvCategories: General Medicine News, Oncologists1Tweet-
Join our collaborators at @OncobitesTv for an interview featuring @DrCrisPadua as he shares research on larotrectinib as an effective treatment for TRK fusion breast cancer. Link: https://t.co/k9RIIRx7nl Dr. @ElisaAgostinett Elisa Agostinetto from the Jules Bordet Institute in… https://t.co/YPDzOVivRA https://t.co/I59Ldib4g1
-
-
Mashup Score: 15SABCS24 ONCOALERT | ONCOBITES - 6 month(s) ago
In an interview, Dr. Agostinetto delves into the findings of Dr. Souza, who shares the results of his research explaining why larotrectinib is positioned as an effective and safe treatment option for patients with TRK fusion breast cancer. Dr. Cristiano de P á dua Souza MD, Jules Bordet Institute, Brussels,
Source: www.oncobites.tvCategories: General Medicine News, Oncologists1Tweet-
Join our collaborators at @OncobitesTv for an interview featuring @DrCrisPadua as he shares research on larotrectinib as an effective treatment for TRK fusion breast cancer. Link: https://t.co/k9RIIRx7nl Dr. @ElisaAgostinett Elisa Agostinetto from the Jules Bordet Institute in… https://t.co/YPDzOVivRA https://t.co/I59Ldib4g1
-
-
Mashup Score: 15SABCS24 ONCOALERT | ONCOBITES - 6 month(s) ago
In an interview, Dr. Agostinetto delves into the findings of Dr. Souza, who shares the results of his research explaining why larotrectinib is positioned as an effective and safe treatment option for patients with TRK fusion breast cancer. Dr. Cristiano de P á dua Souza MD, Jules Bordet Institute, Brussels,
Source: www.oncobites.tvCategories: General Medicine News, Oncologists1Tweet-
Join our collaborators at @OncobitesTv for an interview featuring @DrCrisPadua as he shares research on larotrectinib as an effective treatment for TRK fusion breast cancer. Link: https://t.co/k9RIIRx7nl Dr. @ElisaAgostinett Elisa Agostinetto from the Jules Bordet Institute in… https://t.co/YPDzOVivRA https://t.co/I59Ldib4g1
-
-
Mashup Score: 14ESMO 24 | Oncobites - 8 month(s) ago
Explore the latest advances and innovative treatments in precision oncology. For this coverage, we have selected these experts who will share their knowledge and experiences, providing a valuable and enriching perspective for all attendees. Department of Internal Medicine III – Ludwig-Maximilians University of Munich | LMU, Germany. Department of Investigative Therapeutic Cancer, MD Anderson Cancer Center, Texas, USA. Regional Institute of Gastroenterology and Hepatology Prof. Dr. Octavian Fodor, Cluj-Napo
Source: www.oncobites.tvCategories: General Medicine News, Oncologists1Tweet-
inviting you to Join @DavidHongMD 🇺🇸@BenWestphalen 🇩🇪& @RADUVIDRA 🇷🇴 as they discuss resources for physicians to use precision medicine🧬 in oncology. Find out more in this #ESMO24 Precision Oncology @OncobitesTv WEBINAR Available FREE & on demand LINK:https://t.co/vFGFUkPGUm https://t.co/zNHEaALSXt https://t.co/X9xheVKUMa
-
-
Mashup Score: 13ESMO 24 | Oncobites - 9 month(s) ago
Explore the latest advances and innovative treatments in precision oncology. For this coverage, we have selected these experts who will share their knowledge and experiences, providing a valuable and enriching perspective for all attendees. Department of Internal Medicine III – Ludwig-Maximilians University of Munich | LMU, Germany. Department of Investigative Therapeutic Cancer, MD Anderson Cancer Center, Texas, USA. Regional Institute of Gastroenterology and Hepatology Prof. Dr. Octavian Fodor, Cluj-Napo
Source: www.oncobites.tvCategories: General Medicine News, Oncologists1Tweet-
inviting you to Join @DavidHongMD 🇺🇸@BenWestphalen 🇩🇪& @RADUVIDRA 🇷🇴 as they discuss resources for physicians to use precision medicine🧬 in oncology. Find out more in this #ESMO24 Precision Oncology @OncobitesTv WEBINAR Available FREE & on demand LINK:https://t.co/vFGFUkPGUm https://t.co/zNHEaALSXt https://t.co/X9xheVKUMa
-
-
Mashup Score: 13ESMO 24 | Oncobites - 9 month(s) ago
Explore the latest advances and innovative treatments in precision oncology. For this coverage, we have selected these experts who will share their knowledge and experiences, providing a valuable and enriching perspective for all attendees. Department of Internal Medicine III – Ludwig-Maximilians University of Munich | LMU, Germany. Department of Investigative Therapeutic Cancer, MD Anderson Cancer Center, Texas, USA. Regional Institute of Gastroenterology and Hepatology Prof. Dr. Octavian Fodor, Cluj-Napo
Source: www.oncobites.tvCategories: General Medicine News, Oncologists1Tweet-
inviting you to Join @DavidHongMD 🇺🇸@BenWestphalen 🇩🇪& @RADUVIDRA 🇷🇴 as they discuss resources for physicians to use precision medicine🧬 in oncology. Find out more in this #ESMO24 Precision Oncology @OncobitesTv WEBINAR Available FREE & on demand LINK:https://t.co/vFGFUkPGUm https://t.co/zNHEaALSXt https://t.co/X9xheVKUMa
-
-
Mashup Score: 13ESMO 24 | Oncobites - 9 month(s) ago
Explore the latest advances and innovative treatments in precision oncology. For this coverage, we have selected these experts who will share their knowledge and experiences, providing a valuable and enriching perspective for all attendees. Department of Internal Medicine III – Ludwig-Maximilians University of Munich | LMU, Germany. Department of Investigative Therapeutic Cancer, MD Anderson Cancer Center, Texas, USA. Regional Institute of Gastroenterology and Hepatology Prof. Dr. Octavian Fodor, Cluj-Napo
Source: www.oncobites.tvCategories: General Medicine News, Oncologists1Tweet-
inviting you to Join @DavidHongMD 🇺🇸@BenWestphalen 🇩🇪& @RADUVIDRA 🇷🇴 as they discuss resources for physicians to use precision medicine🧬 in oncology. Find out more in this #ESMO24 Precision Oncology @OncobitesTv WEBINAR Available FREE & on demand LINK:https://t.co/vFGFUkPGUm https://t.co/zNHEaALSXt https://t.co/X9xheVKUMa
-
Join our collaborators at @OncobitesTv for an interview featuring @DrCrisPadua as he shares research on larotrectinib as an effective tx for TRK fusion #BreastCancer straight out of #SABCS24 Link to view: https://t.co/SPBw9mdKdM Dr. @ElisaAgostinett Elisa Agostinetto from… https://t.co/eXuCQI7zW3 https://t.co/WWpR0j2VYF